Alzheimer's disease research requires extensive neuropathology support services. Clinicians in the Clinical Core need to know whether a given individual had Alzheimer's disease or some other dementing illness. Thus, autopsy follow-up is needed on patients and controls enrolled in the clinical diagnosis and therapeutic trials. In addition, for genetic studies of familial Alzheimer's disease, definitive post-mortem diagnoses are eventually required for both clinically affected and clinically normal family members. There is also a need for """"""""outreach"""""""" programs providing diagnostic services for demented patients and their families in the community. In addition, since there are no widely accepted animal modes for this devastating illness, researchers require human brain tissue for experimental biochemical, molecular biological, and histological studies. The Neuropathology Core ha therefore been designed to fulfill three specific aims. First, fresh brain tissue will be obtained within 30-60 minutes after death through the Rapid Autopsy Program, a unique feature of this Center. Second, the Staff of the Kathleen Price Bryan Brain Bank will acquire specimens, establish pathological diagnoses, dissect and store brain tissue from demented and control patients, and release specimens to qualified investigators. Third, the Brain Bank will coordinate a routing service for histological neuropathological and neurochemical data. As part of this data management function, the Brain Bank will coordinate its data- gathering activities with those of the Research Clinical Core.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005128-09
Application #
3790033
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-121
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Ghani, Mahdi; Reitz, Christiane; Cheng, Rong et al. (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol 72:1313-23

Showing the most recent 10 out of 97 publications